Eisai Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Eisai ha un patrimonio netto totale di ¥898.3B e un debito totale di ¥219.1B, che porta il suo rapporto debito/patrimonio netto a 24.4%. Le sue attività totali e le sue passività totali sono rispettivamente ¥1,432.9B e ¥534.6B. L'EBIT di Eisai è ¥65.9B rendendo il suo rapporto di copertura degli interessi -8.3. Ha liquidità e investimenti a breve termine pari a ¥291.3B.

Informazioni chiave

24.4%

Rapporto debito/patrimonio netto

JP¥219.10b

Debito

Indice di copertura degli interessi	-8.3x
Contanti	JP¥291.26b
Patrimonio netto	JP¥898.26b
Totale passività	JP¥534.60b
Totale attività	JP¥1.43t

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00

Feb 12

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 11

Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00

Jan 28

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Jan 14

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Jan 13

Eisai Co., Ltd.'s (TSE:4523) Share Price Matching Investor Opinion

Dec 26

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Dec 05

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Nov 21

Earnings Troubles May Signal Larger Issues for Eisai (TSE:4523) Shareholders

Nov 15

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 12

Is Eisai (TSE:4523) Using Too Much Debt?

Oct 15

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Sep 20

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Sep 05

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Aug 08

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Jul 25

Is Eisai (TSE:4523) A Risky Investment?

Jul 11

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Jul 11

Eisai Co., Ltd.'s (TSE:4523) P/E Is On The Mark

Jun 10

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Apr 11

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Mar 18

Eisai's (TSE:4523) Dividend Will Be ¥80.00

Mar 04

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ¥761.1B ) di 4523 superano le sue passività a breve termine ( ¥381.6B ).

Passività a lungo termine: Le attività a breve termine di 4523 ( ¥761.1B ) superano le sue passività a lungo termine ( ¥153.0B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 4523 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 4523 è aumentato da 17% a 24.4% negli ultimi 5 anni.

Copertura del debito: Il debito di 4523 non è ben coperto dal flusso di cassa operativo ( 8.6% ).

Copertura degli interessi: 4523 matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.

Bilancio

Scoprire le aziende sane

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/02/13 11:32
Prezzo dell'azione a fine giornata	2025/02/13 00:00
Guadagni	2024/12/31
Guadagni annuali	2024/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Eisai Co., Ltd. è coperta da 26 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Atsushi Seki	Barclays
Koichi Mamegano	BofA Global Research
Aaron Ho	CFRA Equity Research

Eisai Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Is Eisai (TSE:4523) Using Too Much Debt?

Is Eisai (TSE:4523) A Risky Investment?

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Recent updates

Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued after recent price drop

Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Eisai Announces FDA Approval for Leqembi in US

Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA (Pembrolizumab) Plus LENVIMA (Lenvima) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

Price target decreased by 7.7% to JP¥6,103

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Eisai Co., Ltd.'s (TSE:4523) Share Price Matching Investor Opinion

Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in Mexico

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Eisai Co., Ltd. and Biogen Inc. Announce "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

First half dividend of JP¥80.00 announced

Earnings Troubles May Signal Larger Issues for Eisai (TSE:4523) Shareholders

Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s Disease

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Eisai Completes Rolling BLA Submission for Subcutaneous Maintenance Dosing of Leqembi® (lecanemab-irmb) in the US

Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing

Eisai Co., Ltd. Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference

Is Eisai (TSE:4523) Using Too Much Debt?

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024

BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

New minor risk - Earnings quality

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 17%

Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International Conference

New minor risk - Share price stability

Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and Research

Eisai Announces Approval for the Treatment of Alzheimer's Disease in Israel

Is Eisai (TSE:4523) A Risky Investment?

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Final dividend of JP¥80.00 announced

High number of new directors

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Full year 2024 earnings: EPS exceeds analyst expectations

Eisai Co., Ltd.'s (TSE:4523) P/E Is On The Mark

Consensus EPS estimates increase by 10%, revenue downgraded

Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

High number of new directors

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Now 21% overvalued

Eisai's (TSE:4523) Dividend Will Be ¥80.00

Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025

Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in China

Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Eisai Co., Ltd., Annual General Meeting, May 22, 2024

NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others.